Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Inclusion Criteria: * Written informed consent/Assent * Male or female between 2 and 16 years, inclusive, at time of Signing Informed Consent/Assent * Have a confirmed and documented clinical diagnosis of Primary Immune Deficiency Disorder, including hypogammaglobulinemia or agammaglobulinemia. * Have received IGIV therapy which was maintained at a steady dose (± 25% of the mean dose) for at least 3 months prior to study entry, and have maintained a trough IgG level at least 500mg/dL prior to receiving BIVIGAM®. * Subjects and/or parents/legal guardians must be able to understand and adhere to the study visit schedule and all other protocol requirements. Exclusion Criteria: * Known intolerance to immunoglobulins or comparable substances (e.g. vaccination reaction). * Known intolerance to proteins of human origin or known allergic reactions to components of the study product(s). * Any previous randomization/participation in this clinical study must be discussed with and approved by the medical director (or designee). * Inability or lacking motivation to participate in the study. * Medical condition, laboratory finding, or physical exam finding (specify, e.g., vital signs outside of specific range that precludes participation. Per lab results at the Screening visit through Baseline. * Confirmed Screening visit laboratory results ˃2.5 X ULN as defined for pediatric populations for any of the following: ALT (alanine aminotransferase/SGPT), AST (aspartate aminotransferase/SGOT), LDH (lactate dehydrogenase), BUN (blood urea nitrogen), Serum creatinine * Has selective IgA deficiency or demonstrated antibodies to IgA. * History of thrombotic complications of IGIV therapy or history of (deep vein thrombosis)DVT. * Current use of daily corticosteroids (\>10 mg of prednisone equivalent/day),immunosuppressants or immunomodulators are not allowed unless approved in advance by the medical monitor. Intermittent use of corticosteroids during the study is allowed if medically necessary. * Positive diagnosis of hepatitis B or hepatitis C. * Positive human immunodeficiency virus (HIV) test. * Subject has had a serious bacterial infection (SBI) within the last 3 months. * Subject has an active infection and is receiving antibiotic therapy for the treatment of this infection at the time of Screening. Note: if the subject is deemed a Screen Failure due to a nonserious active infection requiring antibiotic therapy, the subject may be rescreened 3 or 4 weeks (depending on drug administration schedule) after the initial screening. * Subject has a history of thrombotic events (including deep vein thrombosis, myocardial infarction, cerebrovascular accident and pulmonary embolism) within 6 months before 1st IGIV dose or has preexisting risk factors for thrombotic events. * Acquired medical condition known to cause secondary immune deficiency such as chronic lymphacitic leukemia, lymphoma or multiple lymphoma. * Subjects with protein-losing enteropathies, hypoalbuminaemia. * Females taking oral contraceptives. * Pregnancy or unreliable contraceptive measures or lactation period (females of childbearing potential (female capable of becoming pregnant) only. Males capable of reproduction must agree to a double barrier method of contraception during their study participation.